Dec 23rd, 2025
Unlock key findings in Late-Breaking Science sessions
Fefteen Late-Breaking Science presentations headline #ISC26 in daily Main Events.
Please check the #ISC26 Online Program Planner for the most current list of abstracts in the Main Events as new Late-Breaking Science is being added.
- The Chemical Optimization of Cerebral Embolectomy (CHOICE2) Trial: Main Results
- Recombinant Factor VIIa for Spontaneous Intracerebral Hemorrhage Within Two Hours of Onset. The FASTEST Trial
- The Effect of Treatment on Cognitive Function in Patients With Asymptomatic Carotid Artery Stenosis: The CREST-2 Trial
- Factor XIa Inhibition With Asundexian in Acute Non-Cardioembolic Stroke or High-Risk Transient Ischemic Attack: Primary Results of the OCEANIC-STROKE Trial
- Tenecteplase for Acute Nonlarge Vessel Occlusion at 4.5-24 Hours
- Intravenous Tenecteplase Plus Endovascular Thrombectomy vs. Endovascular Thrombectomy Alone on 4.5 to 24 Hours After Stroke Due to Basilar Artery Occlusion: A Multicenter Randomized Controlled, Clinical Trial (ATTENTION LATE)
- Endovascular Treatment With or Without Preceding Intravenous Tenecteplase in Patients With Late-Window Acute Ischemic Stroke Due to Middle Cerebral Artery Occlusion (TNK-PLUS): A Multicenter Prospective Open-Label, Blinded Endpoint, Phase 3, Randomized Controlled Trial
- The EMBOLISE Study: Embolization of the Middle Meningeal Artery With ONYXTM Liquid Embolic System in the Treatment of Subacute and Chronic Subdural Hematoma
- Tirofiban for Branch Atheromatous Disease-Related Stroke: A Randomized Double-Blind, Placebo-Controlled Trial
- Final Results of the SPAN2 Trial
- The I-ACQUIRE Trial of Constraint Induced Movement Therapy for Infants/Toddlers With Perinatal Arterial Ischemic Stroke
- Endovascular Treatment of Medium Vessel Occlusion Strokes With Moderate or Higher Clinical Severity
- Loberamisal for Acute Ischaemic Stroke (LAIS): A Multicenter Randomized Double-Blind, Parallel, Placebo-Controlled Phase 3 Clinical Trial
- LT3001 Improves Functional Outcomes in Disabling Acute Ischemic Stroke: Results From Two Phase 2 Trials
Efficacy and Safety of Chuanzhi Tongluo Capsule for Acute Ischemic Stroke Patients Without Large or Medium-Sized Vessel Occlusion (CONCERN): A Multicenter Double-Blind Randomized Control Trial
